Head and neck diseases

To define a more precise and personalised treatment by defining new molecular prognostic and predictive tools for patients with squamous-cell carcinoma (SCC).
To define markers of detection and prognosis of HPV-induced oropharyngeal SCC, in order to obtain an early diagnosis and personalised treatment for this group of patients.
To find treatment biomarkers for induced late toxicity, in order to prevent and treat this appropriately.
To implement the use of immunotherapy for oropharyngeal SCC.
To improve transoral head and neck surgery to lead to an improvement in quality of life, with safe results.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >= 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Zandberg D.P., Algazi A.P., Jimeno A., Good J.S., Fayette J., Bouganim N., Ready N.E., Clement P.M., Even C., Jang R.W., Wong S., Keilholz U., Gilbert J., Fenton M., Braña I., Henry S., Remenar E., Papai Z., Siu L.L., Jarkowski A., Armstrong J.M., Asubonteng K., Fan J., Melillo G., Mesía R.

EUROPEAN JOURNAL OF CANCER (ISSN: 0959-8049) 2019

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Taberna, Miren; Oliva, Marc; Mesia, Ricard;

FRONTIERS IN ONCOLOGY (ISSN: 2234-943X) 2019

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions

Guigay J., Tahara M., Licitra L., Keilholz U., Friesland S., Witzler P., Mesía R.

FRONTIERS IN ONCOLOGY (ISSN: 2234-943X) 2019

The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer.

Castet F, Brenes J, Taberna M, Mesía R

CURRENT OPINION IN ONCOLOGY (ISSN: 1040-8746) 2019

Endoscopic type 3 tympanoplasty: Functional outcomes in chronic otitis media

Bartel R., Cruellas F., Hamdan M., Benjumea F., Huguet G., Gonzalez-Compta X., Cisa E., Manos M.

ACTA OTORRINOLARINGOLOGICA ESPANOLA (ISSN: 0001-6519)2020

Valor predictivo y pronóstico de la composición corporal y el hábito tabáquico en pacientes de cáncer de orofaringe según su asociación al virus del papiloma humano

Mesia Nin, Ricard (Principal investigator (PI))

Funder:

• FIS-Instituto de Salud Carlos III

1/1/2020 - 31/12/2022

Estudio de fase I para evaluar la seguridad, la tolerabilidad y la eficacia de VCN-01 en combinación con Durvalumab (MEDI4736) en pacientes con carcinoma de células escamosas de cabeza y cuello recurrente / metastásico.

Mesia Nin, Ricard (Principal investigator (PI))

Funder Reference:

• ICO-VCN-H&N-2018

20/2/2019 - 20/2/2024

DA phase II study of Durvalumab (MEDI4736) plus Tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma-the duthy trial

Taberna Sanz, Miren (Principal investigator (PI))

Funder Reference:

• GETNE-T1812

28/2/2019 - 28/2/2019

A phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201A, an anti-HER2-antibody drug conjugate, versus treatment of investigator's choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DMI

Vazquez Fernandez, Silvia (Principal investigator (PI))

Funder Reference:

• DS8201-A-U301

20/6/2019 -

The AIM-HN and SEQ-HN study: a 2 cohort, non-comparative, pivotal study evaluating the efficacy of Tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with HRAS mutations (AIM-HN) and the impact of HRAS mutations on response to first line systemic therapies for HNSCC (SEQ-HN)

Taberna Sanz, Miren (Principal investigator (PI))

Funder Reference:

• KO-TIP-007

27/5/2019 -

Other Research Lines: The role of HPV on benign nasal disorders; TC evaluation of nasosinusal anatomy and its surgical implications; Genetic disorder and surgical treatment for patients with Rendu Osler Weber disease; Impact of body composition in head and neck cancer oncospecific treatments.